Cargando…

Corrigendum: JAK1/2 inhibitor baricitinib improves skin fibrosis and digital ulcers in systemic sclerosis

Detalles Bibliográficos
Autores principales:	Hou, Zhanying, Su, Xuehan, Han, Guangming, Xue, Ruzeng, Chen, Yangxia, Chen, Ye, Wang, Huan, Yang, Bin, Liang, Yunsheng, Ji, Suyun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9850223/ https://www.ncbi.nlm.nih.gov/pubmed/36687420 http://dx.doi.org/10.3389/fmed.2022.1125836

Ejemplares similares

JAK1/2 Inhibitor Baricitinib Improves Skin Fibrosis and Digital Ulcers in Systemic Sclerosis
por: Hou, Zhanying, et al.
Publicado: (2022)

Successful treatment of ulcerated pyoderma gangrenosum with baricitinib, a novel JAK inhibitor
por: Scheinberg, Morton, et al.
Publicado: (2021)

Systemic sclerosis cutaneous expression: Management of skin fibrosis and digital ulcers
por: Starnoni, Marta, et al.
Publicado: (2021)

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies
por: Sanchez, Gina A. Montealegre, et al.
Publicado: (2018)

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
por: Taylor, Peter C., et al.
Publicado: (2023)

Efficacy of Combination Therapy With The JAK Inhibitor Baricitinib In The Treatment of COVID-19
por: Thoms, Brendan Lawless, et al.
Publicado: (2021)

Efficacy of Combination Therapy with the JAK Inhibitor Baricitinib in the Treatment of COVID-19
por: Thoms, Brendan L., et al.
Publicado: (2022)

Which is the Ideal JAK Inhibitor for Alopecia Areata – Baricitinib, Tofacitinib, Ritlecitinib or Ifidancitinib - Revisiting the Immunomechanisms of the JAK Pathway
por: Sardana, Kabir, et al.
Publicado: (2023)

Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
por: Jabbari, Ali, et al.
Publicado: (2015)

Changes in selected haematological parameters associated with JAK1/JAK2 inhibition observed in patients with rheumatoid arthritis treated with baricitinib
por: Kay, Jonathan, et al.
Publicado: (2020)

Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells
por: Liu, Chang, et al.
Publicado: (2019)

Emerging systemic JAK inhibitors in the treatment of atopic dermatitis: a review of abrocitinib, baricitinib, and upadacitinib
por: Nezamololama, Novin, et al.
Publicado: (2020)

JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib
por: Traves, Paqui G, et al.
Publicado: (2021)

Corrigendum to: Systemic sclerosis-related digital ulcers; a pilot study of cutaneous oxygenation and perfusion
por: Marjanovic, Elizabeth, et al.
Publicado: (1999)

JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial
por: Tuttle, Katherine R, et al.
Publicado: (2018)

A Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro
por: Murakami, Kohei, et al.
Publicado: (2017)

Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells
por: Arnold, Rouven, et al.
Publicado: (2021)

Baricitinib: The First Jak Inhibitor Approved in Europe for the Treatment of Moderate to Severe Atopic Dermatitis in Adult Patients
por: Radi, Giulia, et al.
Publicado: (2021)

Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats
por: Patel, Nikita M., et al.
Publicado: (2023)

Case report: JAK1/2 inhibition with baricitinib in the treatment of STING-associated vasculopathy with onset in infancy
por: Wu, Jianqiang, et al.
Publicado: (2023)

Dynamics of digital ulcers in systemic sclerosis
por: Bobeică, Carmen, et al.
Publicado: (2020)

Dynamics of digital ulcers in systemic sclerosis
por: Bobeică, Carmen, et al.
Publicado: (2020)

The JAK1/2 Inhibitor Baricitinib Mitigates the Spike-Induced Inflammatory Response of Immune and Endothelial Cells In Vitro
por: Barilli, Amelia, et al.
Publicado: (2022)

Registry Evaluation of Digital Ulcers in Systemic Sclerosis
por: Galluccio, Felice, et al.
Publicado: (2010)

Optimal management of digital ulcers in systemic sclerosis
por: Abraham, Shawn, et al.
Publicado: (2015)

Baricitinib in severe and refractory peripheral ulcerative keratitis: a case report and literature review
por: Calvo-Río, Vanesa, et al.
Publicado: (2022)

The Relationship between Smoking, Raynaud's Phenomenon, Digital Ulcers, and Skin Thickness in the Waikato Systemic Sclerosis Cohort
por: Silva, Cherumi, et al.
Publicado: (2022)

Application of Baricitinib in Dermatology
por: Zhang, Jingya, et al.
Publicado: (2022)

Baricitinib treatment for refractory skin changes in POEMS syndrome: a case report
por: Xie, Jingjing, et al.
Publicado: (2023)

Crosstalk between the JAK2 and TGF-β1 signaling pathways in scleroderma-related interstitial lung disease targeted by baricitinib
por: Wang, Dandan, et al.
Publicado: (2023)

Efficacy of JAK inhibitors in Ulcerative Colitis
por: Ferrante, Marc, et al.
Publicado: (2020)

Baricitinib for the treatment of rheumatoid arthritis
por: Urits, Ivan, et al.
Publicado: (2020)

Baricitinib and primary biliary cholangitis
por: Gordon, Stuart C., et al.
Publicado: (2021)

Baricitinib for the Treatment of Alopecia Areata
por: Freitas, Egídio, et al.
Publicado: (2023)

Effect of baricitinib in regulating programmed death 1 and ligand programmed cell death ligand 1 through JAK/STAT pathway in psoriasis
por: Deepak, H. B., et al.
Publicado: (2022)

Baricitinib alleviates lipopolysaccharide‑induced human periodontal ligament stem cell injury and promotes osteogenic differentiation by inhibiting JAK/STAT signaling
por: Yang, Ping, et al.
Publicado: (2022)

Association of antiphospholipid antibodies with active digital ulceration in systemic sclerosis
por: Martin, Mickaël, et al.
Publicado: (2019)

Baricitinib with cyclosporine eliminates acute graft rejection in fully mismatched skin and heart transplant models
por: Abboud, Ramzi, et al.
Publicado: (2023)

Successful treatment of hip involvement in SAPHO syndrome with baricitinib
por: , Wuriliga, et al.
Publicado: (2022)

15. Eosinophilic pneumonitis secondary to baricitinib
por: Yein, Khin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qedb2cohmnl5hqpm2amgfr1669